Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that Wockhardt Bio AG, a subsidiary of the Company, has incorporated a new Wholly Owned Subsidiary in Ireland by the name Wockhardt Antibiotics (Ireland) Limited. Consequent to the incorporation, Wockhardt Antibiotics (Ireland) Limited has become a Step-Down Subsidiary of the Company.
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Wockhardt Limited, through its subsidiary Wockhardt Bio AG, has incorporated a new wholly owned step-down subsidiary in Ireland named Wockhardt Antibiotics (Ireland) Limited on 7th April 2025. The new entity has an initial capital of EUR 100 (100 shares at EUR 1 each) and is yet to commence business operations. Its main purpose is to help channelise Wockhardt's antibiotic products across the European Union. The entity belongs to the pharmaceuticals industry, and 100% of its shares are held by Wockhardt Bio AG. No related party transaction or regulatory approvals are involved.
This move is a strategic step to expand Wockhardt's antibiotic business footprint in the EU market, though the new entity is not operational yet and the financial outlay is minimal, so near-term impact on stock or financials is likely negligible.